Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human TROP-2 in serum, plasma and cell culture supernatants.
It is for research use only.
Assay Type | Sandwich-ELISA |
Analyte | Soluble TROP-2 |
Format | 96-wells plate breakable into 12 x 8 wells strips |
Reactivity | Human |
Sensitivity | 46.875 pg/mL |
Assay Time | 1.75 hr |
Sample volume | 50 μL |
Range | 46.875 pg/mL-12000 pg/mL |
Sample Type | Cell Culture Supernatants, Plasma, Serum. |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, each ELISA plate needs to set the standard curve. The minimum detectable concentration of CEA032-C02 is less than 46.875 pg/mL.
ID | Components | Size |
CEA032-C01 | Pre-coated Anti-TROP-2 Antibody Microplate | 1 plate |
CEA032-C02 | Human TROP-2 Standard | 20 μg ×2 |
CEA032-C03 | Biotin-Anti-TROP-2 Antibody Con. Solution | 400 μL |
CEA032-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
CEA032-C05 | Streptavidin-HRP Con. Solution | 500 μL |
CEA032-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
CEA032-C07 | 20× Washing Buffer | 50 mL |
CEA032-C08 | Sample Dilution Buffer | 15 mL ×2 |
CEA032-C09 | Substrate Solution | 12 mL |
CEA032-C10 | Stop Solution | 6 mL |
Price(USD) : $610.00
Price(USD) :
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sacituzumab govitecan | IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132 | Approved | Immunomedics Inc, Gilead Sciences Inc | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Brain metastases; Mesothelioma; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Hormone-Resistant Prostate Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Solid tumours; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
Datopotamab deruxtecan | DS-1062a; DS-1062; Dato-DXd; S-1062a | Approved | Daiichi Sankyo Co Ltd | Datroway, DATROWAY | Japan | Breast Neoplasms | Daiichi Sankyo Co Ltd | 2024-12-27 | Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Carcinoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Sacituzumab tirumotecan | SKB-264; MK-2870; SKB264; sac-TMT | Approved | Klus Pharma Inc | 佳泰莱 | Mainland China | Triple Negative Breast Neoplasms | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2024-11-22 | Triple Negative Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SHR-A1921 | SHR-A1921; SHRA1921; SHR-1921 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
ESG-401 | STI-3258; OQY-3258; ESG-401 | Phase 3 Clinical | Shanghai Escugen Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer | Details |
FDA018 Antibody Drug Conjugate | FDA018-ADC; FDA-018-ADC | Phase 3 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
GQ-1010 | GQ-1010; BHV1510; BHV-1510; GQ1010; PBI-410 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Trop2 CAR-NK cell therapy(Henan Provincial Cancer Hospital) | Phase 2 Clinical | Henan Provincial Cancer Hospital | Carcinoma, Non-Small-Cell Lung | Details | |
OBI-992 | BSI-992; BSI992; R-992; OBI-992 | Phase 2 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
JSKN-016 | JSKN016; JSKN-016 | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
IBI130 | IBI130; IBI-130 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
Anti TROP2 antibody drug conjugate ADC(Fudan University) | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours; Lung Neoplasms | Details |
BAT-8008 | BAT-8008; BAT8008 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Triple Negative Breast Neoplasms | Details |
DB-1305 | DB1305; BNT325; BNT-325; DB-1305 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
JS-108 | DAC-002; JS-108; DAC-002/JS108 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms | Details |
IBR-822 | IBR822; IBR-822 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details |
DXC-1002 | DXC1002; DXC-1002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours | Details |
DS-001 | DS001; DS-001 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Dartsbio Pharmaceuticals Ltd | Neoplasms | Details |
FZ-AD004 | FZ-AD004 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details |
BCG-011 | DM-001; BCG-011 | Phase 1 Clinical | Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.